Petra Szeszula
CEO
BrainZell
BrainZell develops stem cell-based models of the human brain for drug discovery and neurological research. These advanced models offer a more accurate representation of human brain function compared to traditional animal models, accelerating the development of new therapies for neurological disorders.
- Biotechnology
Updated 18 months ago
Funding
Raised to date
$1.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional drug discovery for neurological disorders relies heavily on animal models, which often fail to accurately replicate human brain physiology and disease pathology. This leads to high failure rates in clinical trials and delays the development of effective therapies.
Solution
BrainZell offers a high-throughput platform for preclinical drug discovery and neurological research based on human induced pluripotent stem cell (iPSC)-derived brain organoids. Their platform generates scalable and reproducible 3D human brain models that more closely mimic human neural biology compared to animal models. These "minibrains" enable researchers to assess drug efficacy, toxicity, and mechanisms of action with improved patient relevance. BrainZell's platform supports target validation, lead optimization, and neurosafety testing, accelerating the development of therapies for neurological diseases.
Target Audience
BrainZell's primary customers are pharmaceutical companies, biotech firms, and academic research institutions involved in drug discovery and development for neurological disorders.
Features
- High-throughput production of brain organoids from human iPSCs with rigorous quality control at every stage
- Customizable iPSC sourcing, including biobank-derived, clinician-sourced, and user-supplied options
- Dynamic testing capabilities, including toxicity assessments and calcium imaging
- Ability to co-culture microglia for neuroimmune studies
- Single-organoid precision, ensuring traceability of all acquired data
- Scalable assays for screening extensive compound libraries
- Custom treatment regimens, including single dose and repeated exposure possibilities
- Comprehensive analytical techniques, including live assays, liquid biopsies, and fixed organoid assays